Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Theranostic”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 10 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT06247995
What this trial is testing

A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 20
Very early researchStudy completedNCT07299253
What this trial is testing

Preclinical Safety Evaluation and First-in-Human Translational Study of [177Lu]Lu-TEFAPI-06

Who this might be right for
Metastatic Solid Tumors (Any Localization)
Lanzhou University Second Hospital 5
Testing effectiveness (Phase 2)Active Not RecruitingNCT04430192
What this trial is testing

Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy

Who this might be right for
Prostatic Neoplasms
Peter MacCallum Cancer Centre, Australia 20
Not applicableStudy completedNCT05644080
What this trial is testing

68Ga/177Lu-PSMA Theranostics in Recurrent Grade 3 and Grade 4 Glioma

Who this might be right for
High Grade Glioma
St. Olavs Hospital 10
Not applicableNot Yet RecruitingNCT06958224
What this trial is testing

Theranostic Approach by Early Multigene Sequencing in Advanced Poor Prognosis Cancers

Who this might be right for
Breast CancerLiver CancerPancreatic Ductal Adenocarcinoma
University Hospital, Lille 360
Testing effectiveness (Phase 2)UnknownNCT02069418
What this trial is testing

Theranostic Tool During Erlotinib Treatment in Non-small Cell Lung Cancer Patient

Who this might be right for
Non-small Cell Lung Cancer Metastatic or Non-small Cell Lung Cancer RecurrentNo EGFR Activating Mutation
University Hospital, Angers 80
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07434180
What this trial is testing

Phase II Trial of Lu-177 FAP-2286 in Patients With Carcinoma of Unknown Primary

Who this might be right for
Cancer of Unknown Primary
Peter MacCallum Cancer Centre, Australia 20
Testing effectiveness (Phase 2)Study completedNCT05146973
What this trial is testing

External Beam Therapy With Theranostic Radioligand Therapy for Oligometastatic Prostate Cancer (ProstACT TARGET)

Who this might be right for
Prostate Cancer
Telix Pharmaceuticals (Innovations) Pty Limited 5
Early research (Phase 1)Looking for participantsNCT07812805
What this trial is testing

SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors

Who this might be right for
Selected Advanced Solid TumorsColorectal Cancer (CRC)Pancreatic Ductal Adenocarcinoma (PDAC)+4 more
SK Life Science, Inc. 100
Testing effectiveness (Phase 2)Looking for participantsNCT06526299
What this trial is testing

Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease

Who this might be right for
Metastatic Castration-Resistant Prostate CarcinomaStage IVB Prostate Cancer AJCC v8
University of Washington 51